Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro.

mAbs - 1 Jan 2000

Liu Haolin, Wei Pengcheng, Zhang Qianqian, Chen Zhongzhou, Aviszus Katja, Downing Walter, Peterson Shelley, Reynoso Lyndon, Downey Gregory P, Frankel Stephen K, Kappler John, Marrack Philippa, Zhang Gongyi

Abstract excerpt

The newly emerging variants of SARS-CoV-2 from South Africa (B.1.351/501Y.V2) and Brazil (P.1/501Y.V3) have led to a higher infection rate and reinfection of COVID-19 patients. We found that the mutations K417N, E484K, and N501Y within the receptor-binding domains (RBDs) of the virus could confer ~2-fold higher binding affinity to the human receptor, angiotensin converting enzyme 2 (ACE2), compared to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19 Drug Treatment

Share to Host-Pathogen Interactions

Share to Molecular Docking Simulation

Share to Protein Interaction Domains and Motifs

Share to Receptors, Virus

Share to SARS-CoV-2

Source

Open in PubMed Open full text

Identifiers

PMID: 34074219
DOI: 10.1080/19420862.2021.1919285
PMCID: PMC8183533

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro.PMID 34074219Read ↗

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab <i>in vitro</i>Semantic proximity Read ↗

Structure-Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda.Semantic proximity Read ↗

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccinationSemantic proximity Read ↗

Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 VariantsSemantic proximity Read ↗

The basis of a more contagious 501Y.V1 variant of SARS-COV-2Semantic proximity Read ↗

Insights into SARS-CoV-2's Mutations for Evading Human Antibodies: Sacrifice and Survival.Semantic proximity Read ↗

Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitroSemantic proximity Read ↗

The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccinesSemantic proximity Read ↗

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species.Semantic proximity Read ↗

Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 VariantsSemantic proximity Read ↗

Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants.Semantic proximity Read ↗

<i>in silico</i> Assessment of Antibody Drug Resistance to Bamlanivimab of SARS-CoV-2 Variant B.1.617Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.